Related Experiment Video

Updated: Oct 18, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

345

The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?

Abhipree Sharma1, Michael Mah1, Rebecca H Ritchie2

  • 1Heart Failure Pharmacology, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.

Pharmacology & Therapeutics
|October 5, 2021
PubMed

Insights

Type 2 diabetes impairs heart function by reducing protective adiponectin signaling. Restoring this pathway may offer new treatments for diabetic cardiomyopathy.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Diabetes mellitus significantly increases heart failure risk, leading to diabetic cardiomyopathy.
  • Diabetic cardiomyopathy involves cardiac fibrosis, hypertrophy, stress, and diastolic dysfunction.
  • Adiponectin, a cardioprotective adipokine, and its receptors are downregulated in type 2 diabetes (T2D) and obesity, impairing cardiac signaling.

Purpose of the Study:

  • To review the link between suppressed adiponectin signaling and cardiac dysfunction in diabetes.
  • To explore adiponectin receptor-mediated pathways in cardioprotection.
  • To discuss therapeutic strategies targeting adiponectin signaling for diabetic cardiomyopathy.

Main Methods:

  • Literature review of current evidence on adiponectin signaling in diabetic cardiomyopathy.
  • Analysis of adiponectin receptor-mediated cardioprotective mechanisms.
  • Summary of existing and potential therapeutic interventions.

Main Results:

  • Suppressed adiponectin signaling is a key factor in T2D-induced cardiac dysfunction.
  • Adiponectin receptors mediate protective effects against cardiac remodeling and lipotoxicity.
  • Current treatment options for diabetic cardiomyopathy are limited.

Conclusions:

  • Impaired adiponectin signaling contributes to diabetic cardiomyopathy.
  • Targeting the adiponectin pathway presents a promising therapeutic avenue for diabetic cardiomyopathy.
  • Further research into adiponectin-based interventions is warranted.

Keywords:
AMPKAdiponectin receptorsCardiomyopathyDiabetesDiastolic dysfunctionPPARα

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

874
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

3.9K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
479
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
566